COVID-19 – Vaccine Distribution Indonesia Challenge & Opportunity
COVID & The New Normal for Supply Chains
Change is Coming
- A vaccine cold chain is much more stringent than even regular Pharma Cold Chain
- Vaccine development is happening at breakneck pace. A broken supply chain could derail this very quickly.
- Indonesia as the worlds largest archipelago brings with it a whole new series of challenges.
- This will require military precision to ensure vaccines arrive at destination “fit for purpose”.
- It is of critical importance that a vaccine is turned into a VACCINATION
Vaccine non negotiables
The vaccine must maintain its properties from point of manufacture to point of end use.
Maintain specific temperature range, typically 2 Deg C to 8 Deg C (Driven by Vaccine type)
Non negotiables include
- Maintain specific temperature range, typically 2 Deg C to 8 Deg C (Driven by Vaccine type)
- Impacted by Temperature, Barometric Pressure, Radiation/Light, Damage
- Must have a record of these parameters throughout the end – end journey.
- Must have specific SOP’s certified by International body/bodies.
- Must have specially trained personnel in vaccine handling
The Geographical Challenge
98 Cities all but 2 of which are a million plus persons
Almost 84,000 villages
MAKE VS BUY
- Importation of vaccine from a certified distributor, shortens development time.
- Can start vaccinating people as soon as vaccine is released.
- Buy a % of initial finished vaccines and bulk supply a quantity to fill and finish in Indonesia
- Making allows complete end–end in country control
- Potentially delayed start but thereafter timeline driven by Indonesia
- Forces the issue resolution of all infrastructure concerns
- Will help accelerate training & bring Indonesian standards inline with WHO & Global regulations
- Will have a knock-on effect of lifting total Indonesian healthcare system
- Will provide career path with good paying jobs in an ever-increasing health & life science industry
Will provide a boost to improve Indonesian “Cold Chain” logistics, impacting all fresh, chilled and frozen products nationwide.
Vaccines being considered are required to be transported stored and distributed at their designated temperatures 2DegC to 8DegC.
Will be affected by temp. changes, Barometric pressure, exposure to radiation/light, damage
Packaging examples : Envirotainer
Container vaccine storage capacity will vary depending on container model.
The RKN E1 IS A pallet size container based on 2nd generation active temperature control system and utilizes compressor cooling
- Electric heating technology
- To meet requirements of pharmaceutical industry for smaller shipments
The RK E1 CONTAINER MAINTAINS TEMPS OF +2 TO +8 RANGEDEG c
- Controlled room temp +15 to +25 deg C range
- Or at any chosen set temps between +0 to 25deg C
- If manufacturing is to take place in Indonesia
- Confirmation of vial manufacturing capacity
- Syringe manufacture will need to be improved
- Current Indonesian syringe manufacturing is at 100mm units
- Vaccine hubs from which last mile carriers take the vaccine the remainder of the way.
- With the potential to deploy mobile health clinics.
- Logically these would follow the population centres
- These means that the National distribution skeleton is in place.
- The white space is the rural areas where investment to build cold chain facilities can be targeted, Lamongan development being considered is a prime example.
- Another opportunity is that the vaccines being considered in Indonesia do not require the extreme temperatures required for other types of vaccine.
Opportunities (Patient Centric)
- Vaccinations will have to happen in waves, driven by availability, with the goal being to achieve Herd Immunity.
- Herd Immunity will require at least 70% of total population being vaccinated (189mm) people.
- The vaccine will require 2 doses each person, equals 378mm doses Indonesian target doses should therefore be a minimum of 400mm doses.
- Larger employers could offer their in-house medical facilities for employee vaccinations.
- Manufacturers that start to build networks and collaborations to meet consumers where they live, and work will be better equipped to deliver medicines to all patients regardless of socioeconomic conditions.
- Use of Cloud based real time performance monitoring of vaccine supply chain from point of manufacture to point of vaccine administered.
- Temperature tracking in storage and throughout distribution with alerts for deviations to allow operators to react in real-time.
- Big Data Analytics helps providers pharmacists and vaccine administrators to share data.
- Tracking things like # of vials used, # of vials shipped, expected delivery dates
- Creating a virtual feedback loop to improve J.I.T. delivery.
- Accelerate use of IoMT specifically wearables linked to Apps.
- This pandemic is unlike anything experienced in modern times.
- Healthcare systems are stretched, but the failure to efficiently and equitably deploy a vaccine are severe.
- A patient focussed, fully connected vaccine supply chain will help save lives, reduce additional suffering and improve the economy.
- What ever is built now will improve Indonesia’s healthcare system and peoples lives in the future.